Eli Lilly recently announced that by July 1, 2026, Medicare beneficiaries in the United States will be able to access the company's discounted obesity treatment drugs.

The announcement of this timeline highlights Eli Lilly's active progress in expanding the accessibility of its weight loss medication. The company is working with relevant medical insurance institutions to enable eligible patient groups to benefit from its innovative therapy as soon as possible. This move is expected not only to alleviate the medical burden on patients with obesity, but also reflects the trend of pharmaceutical companies collaborating with public health insurance systems to promote the widespread availability of important drugs. As a key component of Eli Lilly's product line, the inclusion of its weight loss medication in insurance coverage will further enhance the market penetration of this drug.